App-Quantinova.ai

FIRST INTERIM ANALYSIS OF ALPINE STUDY: RESULTS OF A PHASE 3 RANDOMIZED STUDY OF ZANUBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Peter Hillmen - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Ibrutinib

PHARMACOKINETICS, PHARMACODYNAMICS, EFFICACY AND SAFETY OF RAVULIZUMAB IN CHILDREN AND ADOLESCENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: INTERIM ANALYSIS OF A PHASE 3, OPEN-LABEL STUDY

Alexander Kulagin - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Paroxysmal nocturnal hemoglobinuria

Eculizumab

INTEGRATED SINGLE CELL ANALYSIS IDENTIFIES UNIQUE MOLECULAR AND FUNCTIONAL FEATURES OF EXTRAMEDULLARY HAEMATOPOIESIS IN HUMANS

Nicole Mende - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

THE EFFECT OF BODY MASS INDEX ON EFFICACY AND SAFETY OF BOSUTINIB OR IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA

Tim H Brmmendorf - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Bosutinib

A SYSTEMS BIOLOGY APPROACH TO DLBCL PREDICTS EMERGENT PHENOTYPES FROM MOLECULAR DYSREGULATION AND IDENTIFIES DISTINCT ROLES FOR NF-KB SUBUNITS CREL AND RELA.

Simon Mitchell - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

WHOLE BODY MRI IS A FEASIBLE AND COST-EFFECTIVE IMAGING MODALITY FOR WORK-UP OF SUSPECTED OR NEWLY DIAGNOSED MULTIPLE MEYLOMA: A RETROSPECTIVE, SINGLE CENTRE COHORT STUDY

Richard Buka - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

MANUFACTURING COMMERCIAL AXICABTAGENE CILOLEUCEL FOR EUROPEAN PATIENTS: A 2-YEAR RETROSPECTIVE ANALYSIS

Louis van de Wiel - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Axicabtagene ciloleucel

STUDY OF THE MACROPHAGE POLARISATION CONTINUUM WITH RELEVANCE TO COVID19

Charlotte Severn - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Glucocorticoid

UPDATED PHARMACODYNAMIC AND SURVIVAL OUTCOMES FROM THE AG221-AML-005 TRIAL OF ENASIDENIB (ENA) PLUS AZACITIDINE (AZA) IN PATIENTS WITH MUTANT IDH2 NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (ND-AML)

Courtney DiNardo - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Vidaza

OUTCOMES BEFORE AND AFTER DOSE REDUCTION IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA RECEIVING BOSUTINIB OR IMATINIB

Michael W Deininger - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Bosutinib

ASSESSING TIME TO DETERIORATION IN HRQOL IN PATIENTS WITH MULTIPLE MYELOMA USING VENETOCLAX IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE COMPARED WITH PATIENTS USING BORTEZOMIB AND DEXAMETHASONE

Philippe Moreau - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

EFFECTIVENESS AND SAFETY OF ROMIPLOSTIM IN PATIENTS WITH NEWLY DIAGNOSED, PERSISTENT AND CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA IN GERMAN ROUTINE CLINICAL PRACTICE: THE OBSERVATIONAL PLATEAU STUDY

Marcel Reiser - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

Romiplostim

CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA RECEIVING CONVENTIONAL THIRD-LINE THERAPY: A MULTICENTER, RETROSPECTIVE, REAL-WORLD STUDY IN THE UNITED KINGDOM

Christopher Fox - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Primary central nervous system lymphoma

N/A

FEWER RED BLOOD CELL TRANSFUSION UNITS AND VISITS ACROSS BASELINE TRANSFUSION BURDEN LEVELS IN PATIENTS WITH BETA-THALASSEMIA TREATED WITH LUSPATERCEPT IN THE PHASE 3 BELIEVE TRIAL

Ali T. Taher - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Beta-thalassemia

luspatercept

DDX3X LOSS IS ASSOCIATED WITH AGGRESSIVE PHENOTYPES IN NON-HODGKIN’S LYMPHOMAS

Atish Kizhakeyil - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non‐Hodgkin Lymphoma

N/A

GOOD OUTCOME OF HIGH-RISK MYELOFIBROSIS IN ELDERLY RECIPIENTS AFTER FULL INTENSITY T-DEPLETE CONDITIONING WITH FLUDARABINE, BUSULFAN, WITH SINGLE AGENT CICLOSPORIN AS GVHD PROPHYLAXIS.

Daniele Avenoso - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Graft-versus-host disease

Cyclosporine A

USE OF THE EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE MULTIPLE MYELOMA QUESTIONNAIRE (EORTC QLQ-MY20): A REVIEW OF THE LITERATURE 25 YEARS AFTER DEVELOPMENT.

Isobel Mcmillan - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

STANDARDIZING NGS-MRD IN AML: AN INTERNATIONAL STUDY BY THE ELN-MRD WORKING PARTY

Michael Heuser - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

TP53

UNUSUAL LABORATORY FEATURES AND CLINICAL COURSE OF HEPARIN INDUCED THROMBOCYTOPENIA IN CARDIOPULMONARY PATIENTS.

Kanval Ali - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Thrombocytopenia

Heparin

ALLOGENEIC STEM CELL TRANSPLANTATION FOR CUTANEOUS T-CELL LYMPHOMA

Daniel Angelov - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Cutaneous T-cell lymphoma

Mycophenolate mofetil

Filters

45280 Abstracts